M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy PharmaphorumAbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.Immunology & InflammationRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its ‘mega-blockbuster’ immunology pipeline. Immunology & Inflammation Read full story Post navigation Previous: Lilly bets up to $800M for BioArctic’s brain delivery techNext: Pfizer drug acquired in Seagen deal disappoints in lung cancer study Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
